Data collection is paused while the tracker is being upgraded. The data below is complete up to 20 August 2026.

Novartis Venture Fund

Switzerland · 33 portfolio companies · first tracked 2 August 2026

Portfolio

CompanySectorStageCountry
Alesta BiotechNetherlands
Amphista Therapeutics United Kingdom
Anaveon BiotechSwitzerland
Aravax BiotechAustralia
Artios Pharma Limited BiotechUnited Kingdom
Arvada Therapeutics BiotechUnited States
AstronauTx BiotechUnited Kingdom
Atalanta BiotechUnited States
Averna Therapeutics BiotechIsrael
CatalYm BiotechGermany
Citryll BiotechNetherlands
Enterprise Therapeutics BiotechUnited Kingdom
Epi Biologics Healthtech, BiotechUnited States
Epsilogen BiotechUnited Kingdom
FoRx Therapeutics BiotechSwitzerland
Fore Biotherapeutics BiotechUnited States
GentiBio BiotechUnited States
Granite Bio BiotechSwitzerland
HYKU Biosciences United States
Immunitas Therapeutics carried forward from 14 August 2026 BiotechUnited States
Kynexis BiotechNetherlands
LoQus23 BiotechUnited Kingdom
Mediar Therapeutics BiotechUnited States
NRG Therapeutics BiotechUnited Kingdom
ONL Therapeutics BiotechUnited States
Protego BiotechUnited States
RhyGaze BiotechSwitzerland
Salvina BiotechSwitzerland
Seawolf BiotechUnited States
Sidewinder Therapeutics BiotechUnited States
SpliceBio BiotechSpain
Tagworks Pharmaceuticals BiotechNetherlands
Vivet Therapeutics SAS BiotechFrance

Recorded changes

Spotted something wrong? Tell us.